Nasdaq plans to delist BNB treasury company Windtree Therapeutics (WINT) for failing to meet compliance requirements as the $700M BNB treasury pivot fails to lift stock


The Block •
Revision history
12 recorded changes
Want your article here?
Promote with Leviathan News